MEDI3902 regulatory update

AstraZeneca's MedImmune LLC unit said FDA granted Fast Track designation to MEDI3902 to prevent nosocomial pneumonia caused by Pseudomonas aeruginosa. MedImmune said MEDI3902 is entering Phase I tria...